A client recently started cenobamate and the dose was increased faster than the prescribed titration. The client now has fever, diffuse rash, facial swelling, and enlarged lymph nodes. Which action is the priority?
1Give the scheduled dose with an antihistamine and reassess the rash in two hours.
2Continue the titration and arrange routine laboratory testing before the next increase.
3Reduce the dose using standing seizure precautions and call at the next clinic visit.
4Hold cenobamate and obtain urgent evaluation for a suspected multiorgan hypersensitivity reaction.✓ Correct answer
Explanation
Fever, rash, facial edema, and lymphadenopathy after rapid cenobamate titration can signal DRESS, a potentially fatal multiorgan hypersensitivity reaction requiring immediate discontinuation evaluation.
Quick answer Treat rash plus systemic symptoms during cenobamate titration as possible DRESS.
Why this is correct Cenobamate must be started low and titrated slowly. Antihistamine or a partial dose reduction does not make ongoing exposure safe when DRESS is suspected.
Easy analogy or mental picture Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.
Memory hook Drug, urgent cue, protective action, and reassessment endpoint.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.
Medication-safety reviewVerify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.